BR9608505A - Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva - Google Patents

Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva

Info

Publication number
BR9608505A
BR9608505A BR9608505A BR9608505A BR9608505A BR 9608505 A BR9608505 A BR 9608505A BR 9608505 A BR9608505 A BR 9608505A BR 9608505 A BR9608505 A BR 9608505A BR 9608505 A BR9608505 A BR 9608505A
Authority
BR
Brazil
Prior art keywords
angiotensin
receptor antagonist
spironolactone
combination therapy
treatment
Prior art date
Application number
BR9608505A
Other languages
English (en)
Portuguese (pt)
Inventor
Todd E Maclaughlan
Joseph R Schuh
Original Assignee
G D Searle E Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G D Searle E Co filed Critical G D Searle E Co
Publication of BR9608505A publication Critical patent/BR9608505A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR9608505A 1995-06-07 1996-06-05 Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva BR9608505A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48608995A 1995-06-07 1995-06-07
PCT/US1996/009342 WO1996040258A2 (en) 1995-06-07 1996-06-05 Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
BR9608505A true BR9608505A (pt) 1999-07-06

Family

ID=23930539

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608505A BR9608505A (pt) 1995-06-07 1996-06-05 Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva

Country Status (16)

Country Link
US (1) US20040102423A1 (2)
EP (1) EP0831911B1 (2)
JP (1) JPH11509838A (2)
KR (1) KR19990022723A (2)
CN (1) CN1192696A (2)
AT (1) ATE216261T1 (2)
AU (1) AU6158096A (2)
BR (1) BR9608505A (2)
CA (1) CA2224222A1 (2)
CZ (1) CZ291268B6 (2)
DE (1) DE69620756T2 (2)
DK (1) DK0831911T3 (2)
ES (1) ES2175098T3 (2)
IL (1) IL122246A (2)
PT (1) PT831911E (2)
WO (1) WO1996040258A2 (2)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU3408801A (en) * 2000-02-18 2001-08-27 Takeda Chemical Industries Ltd Tnf-alpha inhibitors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
KR20150038395A (ko) * 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
MX2011000216A (es) * 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
ES2433225T3 (es) 2009-01-30 2013-12-10 Takeda Pharmaceutical Company Limited Compuesto con anillos condensados y uso del mismo
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
CA2821985C (en) 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
CN102816126A (zh) * 2011-06-07 2012-12-12 中国药科大学 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
BR112018077075A2 (pt) 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1991012001A1 (en) * 1990-02-13 1991-08-22 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
EP0586513A1 (en) * 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
AU5449194A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
WO1996040258A3 (en) 1997-01-23
US20040102423A1 (en) 2004-05-27
DK0831911T3 (da) 2002-07-22
ATE216261T1 (de) 2002-05-15
IL122246A (en) 2004-06-01
ES2175098T3 (es) 2002-11-16
EP0831911A2 (en) 1998-04-01
CZ291268B6 (cs) 2003-01-15
AU6158096A (en) 1996-12-30
CZ384897A3 (cs) 1998-05-13
CA2224222A1 (en) 1996-12-19
JPH11509838A (ja) 1999-08-31
PT831911E (pt) 2002-09-30
WO1996040258A2 (en) 1996-12-19
EP0831911B1 (en) 2002-04-17
DE69620756D1 (de) 2002-05-23
KR19990022723A (ko) 1999-03-25
DE69620756T2 (de) 2002-11-14
IL122246A0 (en) 1998-04-05
CN1192696A (zh) 1998-09-09

Similar Documents

Publication Publication Date Title
DK0831911T3 (da) Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist
WO1996040255A3 (en) Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
AU640417B2 (en) Substituted 5-((tetrazolyl)alkenyl)imidazoles
NO975741D0 (no) Epoksy-steroidalaldosteronantagonist og antiotensin-II-antagonistkombinasjonsterapi for behandling av kongestiv hjertesvikt
IE902139L (en) Imidazolyl alkenoic acids
WO2004082599A3 (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
NZ330889A (en) Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases
EP0437103A3 (en) Substituted 5-(alkyl)carboxamide imidazoles
AU8844491A (en) Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
EP1045636A4 (en) PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR DAMAGED MYOCARD TISSUE
NO160138C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive((4-(4-(4-fenyl-1-piperazinyl)fenoksymetyl)-1,3-dioksolan-2-yl)-metyl)-1h-imidazoler og 1h-1,2,4-triazoler.
NO902632D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolyl-alkensyrer.
WO2002009760A3 (en) Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
CA2110806A1 (en) 4-(1h-pyrrol-1-yl)imidazoles with angiotensin ii antagonist activity
AU6564990A (en) Substituted n-(imidazolyl)alkyl alanine derivatives
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
ES2105939A1 (es) Nuevos pirazoles con actividad antagonista de la angiotensina ii.
MX9709976A (es) Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas.
HU9402429D0 (en) Pyrazolopyrimidin derivatives as angiotensin ii receptor antagonists
MX9709978A (es) Terapia de combinacion de antagonista de aldosterona epoxi-esteroidal y antagonista de angiotensina ii para tratamiento de insuficiencia cardiaca congestiva.
HUP0101549A3 (en) Form vi cristallyc form of 5,6-dichloro-2-(isopropylamino)-1-(betha-l-ribofuranosyl)-1h-benzimidazole
NZ504898A (en) (e)-3-[1-n-butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1h-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt as an endothelin receptor antagonist
DK1273232T3 (da) Fremgangsmåde til fremstilling af herbicidet ethyl-alfa-2-dichlor-5-[4-(difluormethyl)-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl]-4-fluorbenzen-propanoat
TW200501937A (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
AU2003202486A1 (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements